Latest Breaking News On - Surveyor capital - Page 8 : comparemela.com

Sudo gets $116M to develop TYK2 inhibitors for MS, other diseases

Sudo gets $116M to develop TYK2 inhibitors for MS, other diseases
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Chris gagliardiSudo biosciencesEdd flemingScott byrdEnavate sciencesRise fundLife sciences innovationsFrazier life sciencesSciences innovationsVelosity capitalSanofi venturesSurveyor capitalMonograph capitalEventide assetShinichiro fuse

Sudo Biosciences Raises $116M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Sudo biosciencesScott byrdRise fundFrazier life sciencesEnavate sciencesLife sciences innovationsSciences innovationsSanofi venturesSurveyor capitalMonograph capitalEventide asset management

The University of Michigan wrote Sam Altman s venture capital firm a $75M check earlier this year for a new fund

The university’s $17.9 billion endowment has also invested directly in OpenAI and in OpenAI’s corporate venture fund, documents show.

New yorkUnited statesCity ofUnited kingdomTel avivPalm harborAmerican forkJessica mathewsCharlie comptonNick cranceBoca ratonDan federSudo biosciencesLos angelesMichelle carrAtavistik bio

Sanofi-backed Sudo seals $116M series B

Sanofi-backed Sudo seals $116M series B
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesSanofi aubagioSudo biosciencesMerck kgaFrazier life sciencesPatient square capital enavate sciencesRise fundLife sciences innovationsWith sanofi venturesPatient square capitalEnavate sciencesSanofi venturesSurveyor capitalMonograph capitalEventide asset managementVelosity capital

Vanqua Bio Advances Clinical Candidate for Parkinson s Disease, Expands Leadership Team to | Region

CHICAGO, Dec. 12, 2023 (GLOBE NEWSWIRE) Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase (GCase), will enter clinical development

United statesVanqua bioOmer siddiquiBristol myers squibbJesse cedarbaumEli lillyAlyssa paldoJim sullivanRegeneron pharmaceuticalsMovement disordersElan corporationOsage university partnersChief medical officerChief development officerRand sutherlandChief executive officer